Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GRT-R912
- Development stage
- Phase 1
- Lead developer
- Gritstone Oncology
- Modality
- Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GRT-R912 is a self-amplifying messenger RNA (samRNA) vaccine targeting the SARS-CoV-2 spike protein. It is designed for the indication of COVID-19 and is administered via injection. The vaccine aims to stimulate immune responses against SARS-CoV-2.
- Other names
- samRNA-Spikebeta-TCE11samRNA-Spikebeta-TCE-11samRNA-Spikebeta-TCE 11
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on GRT-R912.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GRT-R912.